- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04175587
Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL (RIF)
Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute Promyelocytic Leukaemia (APL) has been known as a type of cancer, seriously endangering human health especially for young adults. It is of great significance to improve its eradication rate. Recent clinical trials show that ATRA plus ATO treatment regimen can result in complete response (CR) in 90-94% of patients and 5-year disease-free survival (DFS) in more than 90% of patients.
However, the ATRA plus ATO treatment regimen can achieve considerate survival rate, patients still need to receive infusion therapy in hospital. If oral arsenic can replace intravenous ATO without reduction of the efficacy, patients would not need to be administered to receive treatment, which would highly increase their quality of lives. The research and development of oral arsenic has therefore become a hotpoint. Professor Huang, Shilin from he 210th Hospital of PLA, according to the Prescription Theory "Jun Chen Zuo Shi", developed and designed an oral arsenic, the Compound Realgar-Indigo Naturalis Formula. Phase I, II Clinical trials have verified the security and efficacy of the Compound Realgar-Indigo Naturalis Formula. Research Team led by Professor Huang, Saijun, Shanghai Institute of Haematology (China), studied Compound Realgar-Indigo Naturalis Formula's mechanism of action from vitro cell lines and mice.
In the following Phase II clinical trial, APL patients received Compound Realgar-Indigo Naturalis Formula solo treatment regime. It resulted in 96.7% of CR and high safety rate Compound Realgar-Indigo Naturalis Formula was approved by the China Food and Drug Administration in 2009. Investigators have done a multi-centre, randomized, controlled, non-inferiority phase 3 clinical trial in China. 242 newly diagnosed APL patients (with newly diagnosed WBC<50×10^9/L) were enrolled. And the result showed that oral arsenic plus retinoic acid has an anti-leukaemic efficacy similar to the intravenous arsenic treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Hao Jiang, MD
- Phone Number: 13601164350
- Email: 2516735116@qq.com
Study Contact Backup
- Name: Sheng ye Lu, PhD & MD
- Phone Number: 15810723933
- Email: lushengye01@126.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed APL patient (with WHO performance status)
- Age 18-70
- ALT and AST of maximum 2·5 times the ULN, and bilirubin concentration of maximum two times the ULN
- Creatinine concentration of maximum three times the ULN
- Performance status of 0-2 grade (ECOG)
- WBC ≤ 10 x 109/L before the treatment
- Informed Consent Paper signed
Exclusion Criteria:
- Cerebral hemorrhage
- Pregnancy
- Concomitant severe psychiatric condition or anything else against the fulfillment of the plan
- Clinically significant arrhythmias or electrocardiogram abnormalities (QT>500ms)
- Refusal to sign off the Informed Consent Paper
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
|
Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
Other Names:
|
Other: Arsenic trioxide Plus Retinoic Acid
Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
|
Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year Event-free Survival (EFS) rate
Time Frame: 2 year after diagnosis
|
treatment failure (no CR after 45-day induction therapy, or no molecular complete remission after 3-month consolidation therapy), relapse (molecular relapse, or haematological relapse); or death from any cause.
|
2 year after diagnosis
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiao-Jun Huang, MD, Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIF & ATRA in NHR APL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Promyelocytic Leukaemia
-
University Hospital Southampton NHS Foundation...Imperial College Healthcare NHS Trust; Royal Devon and Exeter NHS Foundation... and other collaboratorsCompletedLeukaemia (Acute) | Leukaemia (Chronic) | Leukaemia (Acute Myeloid) | Leukaemia (Acute Lymphoblastic) | Leukaemia (Acute Promyelocytic)United Kingdom
-
German AML Cooperative GroupUnknownRelapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic LeukemiaGermany
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina
-
Christian Medical College, Vellore, IndiaUnknownRelapsed Acute Promyelocytic LeukemiaIndia
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAUnited States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
-
Grupo Argentino de Tratamiento de la Leucemia AgudaRecruiting
-
Instituto Nacional de Cancerologia de MexicoCompletedPromyelocytic Leukemia, AcuteMexico
-
PETHEMA FoundationCompletedAcute Promyelocytic LeukemiaSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Neoplasm | Childhood Acute Promyelocytic Leukemia With PML-RARAUnited States, Canada, Puerto Rico
Clinical Trials on Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaboratorsRecruitingChildhood ALL | Arsenic TrioxideChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAcute Myeloid LeukemiaChina
-
Peking University People's HospitalRecruitingAcute Promyelocytic Leukemia | Oral | Induction TherapyChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityTang-Du HospitalRecruitingAcute Promyelocytic LeukemiaChina
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina